PL001 CD19 CAR-T

CD19-directed chimeric antigen receptor T-cell therapy (CAR-T) targeting CD19 · Pell Bio-Med Technology Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for PL001 CD19 CAR-T, covering 2025-05-13 to 2025-05-13. Get the full timeline:

Most recent: Clinical Trial Update: Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma [Phase 1, Phase 2]

See pricing